Search PubMed⌕ Search

Biomedical subjects

M Serrano

Publications and source records attributed to M Serrano.

At least 163 records · Page 9Linked to original sources
PubMed1979

[Hepatosplenic sarcoidosis. Apropos of a case].

We present a case of hepatosplenic sarcoidosis without associated pulmonary affection. We have also revised the literature in this respect with special emphasis on the etiopathogenic aspects. The evolution and treatment followed during the period two liver biopsies were performed. The good response to treatment with steroids, clinically and histopathologically, are commented on.

Female↗
PubMed1977

A controlled study of a dopa decarboxylase inhibitor (benserazide) in the treatment of schizophrenic patients.

In a double-blind controlled study lasting 6 weeks, 32 schizophrenic patients were randomly assigned to one of two treatments: chlorpromazine or benserazide, a dopa decarboxylase inhibitor. Results on each measure were subject to multifactorial analysis of covariance. Benserazide did not appear to be as effective an antipsychotic medicaiton as chlorpromazine. In fact, chlorpromazine was significantly better on measures of tension, excitement, hallucinatory behavior, thinking disturbance, social interest, and drop-out rate. At the relatively low dosages used in this study, it would seem that benserazide had little effect on the cerebral dopa decarboxylase, and it would be worthwhile trying higher dosages.

Adult↗
PubMed1977

[Not Available].

Explore the source record for details and available documents.

History of Pharmacy↗
PubMed1977

[Not Available].

Explore the source record for details and available documents.

History of Medicine↗
PubMed1976

[Not Available].

Explore the source record for details and available documents.

History of Pharmacy↗
PubMed1975

Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. A controled study of drug interaction.

In a double-blind placebo, controlled clinical study, lasting 12 weeks, 48 male and 48 female ambulatory schizophrenic patients were randomly assigned to one of four treatments: placebo; amitriptyline hydrochloride, 125 mg/day; perphenazine, 20 mg/day; or amitriptyline-perphenazine, 20 mg/day. Treatment groups contained an equal number of male and female patients. Perphenazine alone or in combination was substantially more effective in reducing psychopathological disorder than was the placebo, but there was no evidence to indicate the superiority of the amitriptyline-perphenazine combination over perphenazine alone. Amitriptyline alone was not substantially better than placebo and could not be considered an efficacious medication for the maintenance treatment of these patients. Less response to treatment was made by patients with longer-term records of prior hospitalization.

Adult↗
PubMed1975

[Not Available].

Explore the source record for details and available documents.

History of Pharmacy↗
PubMed1972

[Not Available].

Explore the source record for details and available documents.

History of Pharmacy↗